<?xml version="1.0" encoding="UTF-8"?>
<p>The increasing prevalence of DRMs in PLWH has become a serious matter of concern for clinicians and public health entities (
 <xref rid="R4" ref-type="bibr">
  <italic>4</italic>
 </xref>). In our study, we observed a 17.8% prevalence of DRMs, higher than in previous studies (
 <xref rid="R6" ref-type="bibr">
  <italic>6</italic>
 </xref>,
 <xref rid="R7" ref-type="bibr">
  <italic>7</italic>
 </xref>). The proportion of NNRTI resistance mutations was 8.9%, which is potentially associated with the common use of NNRTI in first-line ART regimens. K103N represented one quarter of NNRTI resistance mutations, reducing susceptibility to the first-generation drugs nevirapine and efavirenz (
 <xref rid="R13" ref-type="bibr">
  <italic>13</italic>
 </xref>). Transmission network analyses revealed that K103N was the most frequently shared DRM.
</p>
